PFBT
RCEL icon

Parkside Financial Bank & Trust’s Avita Medical RCEL Stock Holding History

Parkside Financial Bank & Trust’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620 Buy
+150
New +$647 ﹤0.01% 2559

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Parkside Financial Bank & Trust's RCEL Position: Q2 2026 in Review

Parkside Financial Bank & Trust opened a new position in Avita Medical (RCEL) in Q2 2026: 150 shares worth $620. The stake represents ﹤0.01% of the portfolio and ranks #2559 among its holdings.

73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Parkside Financial Bank & Trust held 150 shares of Avita Medical worth $620 as of Q2 2026.
  • Avita Medical was a new Parkside Financial Bank & Trust position in Q2 2026.
  • Avita Medical made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2559 holding.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.